Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus Erlotinib in EGFR-Mutated Metastatic NSCLC
NCT02411448Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2015
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started May 2015; status: active, not recruiting.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02411448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411448.